Advanced Search
YU Wei-wei, WANG Hua-qing, QIAN Zheng-zi, CUI Xiu-zhen, HAO Xi-shan. Clinical Characteristics and Prognosis Analysis of Primary Mediastinal Large B Cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(06): 647-650. DOI: 10.3971/j.issn.1000-8578.2011.06.010
Citation: YU Wei-wei, WANG Hua-qing, QIAN Zheng-zi, CUI Xiu-zhen, HAO Xi-shan. Clinical Characteristics and Prognosis Analysis of Primary Mediastinal Large B Cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(06): 647-650. DOI: 10.3971/j.issn.1000-8578.2011.06.010
shu

Clinical Characteristics and Prognosis Analysis of Primary Mediastinal Large B Cell Lymphoma

  • Department of Lymphoma, Cancer Institute and Hospital of Tianjin Medical University, Sino-US Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Center Prevention and Therapy,Tianjin 300060, China

More Information
  • Received Date: August 08, 2010
  • Revised Date: March 08, 2011
    Graphical Abstract
    • Abstract
  • ObjectiveTo explore the clinical characteristics, treatment patterns and prognostic factors of primary mediastinal large B cell lymphoma( PMLBCL). MethodsClinical records of 25 PMLBCL patients who were admitted at department of lymphoma of Tianjin medical university cancer hospital, from October 1999 to May 2009, to evaluate the influence of clinical characteristics and treatment modality on survival. ResultsThe 5-year overall survival(OS) and progress free survival（PFS）were 56.7% and 54.7%, respectively. Eighteen patients accepted chemoradiotherapy and 7 patients accepted chemotherapy alone. The 2-year PFS were 57.1% and 53.6%, respectively, the outcome had not significant difference（P>0.05）. In univariate analysis, only international prognostic index（IPI）and LDH≥2ULN （upper limit of normal）were found to be the prognostic factors associated with overall surviva1 in PMLBCL. But in multivariate analysis, neither were independent prognostic factors. ConclusionIPI and LDH≥2ULN were associated with the prognosis of PMLBCL. But neither was independent prognostic factors in PMLBCL.Compared with chemotherapy, chemoradiotherapy did not show a better response.
    • FullText(HTML)
    • References (0)
    • Related Articles

  • Related Articles

    [1]SUN Wenjia, YUE Junqiu, WANG Manxiang. Clinicopathological Characteristics and Therapeutic Effect of Patients with Non-small Cell Lung Cancer and Uncommon EGFR Mutations[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1221-1226. DOI: 10.3971/j.issn.1000-8578.2023.23.0431
    [2]XU Wenwen, ZHU Yuxi. Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1129-1134. DOI: 10.3971/j.issn.1000-8578.2021.21.0761
    [3]WU Bili, JIN Yu, ZHOU Xiao, YUAN Xianglin, LI Qianxia. Association Between Single Nucleotide Polymorphisms in ESR Pathway and Risk of Brain Metastasis in NSCLC with EGFR Mutation[J]. Cancer Research on Prevention and Treatment, 2020, 47(10): 746-751. DOI: 10.3971/j.issn.1000-8578.2020.20.0837
    [4]HOU Ran, HU Po, SHI Jian. Research Progress of EGFR T790M Mutation in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(6): 471-476. DOI: 10.3971/j.issn.1000-8578.2020.19.0302
    [5]SU Yudong, CHEN Peng. Research Progress on Brain Metastases to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR-mutated Non-small Cell Lung Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(10): 698-700. DOI: 10.3971/j.issn.1000-8578.2017.17.0240
    [6]LU Chang, SHEN Shujing, MAO Yuhuan, JI Yingying, LI Peipei, CAO Hui, WANG Ye, LI Xingya. Correlation of Tumor Markers with Clinical Efficacy of Advanced Lung Adenocarcinoma Patients with EGFR Mutation[J]. Cancer Research on Prevention and Treatment, 2017, 44(7): 485-488. DOI: 10.3971/j.issn.1000-8578.2017.16.1530
    [7]XU Xiaoyan, XU Xianwei, WANG Hui, YANG Jinhua. Expression of PTEN and EMMPRIN in Lung Adenocarcinoma Tissues and Their Correlation with EGFR Mutation[J]. Cancer Research on Prevention and Treatment, 2017, 44(5): 324-328. DOI: 10.3971/j.issn.1000-8578.2017.05.003
    [8]YANG Zhenhua, YE Liang, FANG Surong, GU Wei. Clinical Significance of Immunohistochemistry in Detecting Epidermal Growth Factor Receptor Mutation in Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 272-276. DOI: 10.3971/j.issn.1000-8578.2016.04.007
    [9]LIU Yongmei, ZHAO Qian, TANG Yuan, ZHANG Yan, LI Yanying, WANG Yongsheng, LU You. Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors for Advanced Squamous Cell Lung Carcinoma Patients with Sensitive EGFR Mutations[J]. Cancer Research on Prevention and Treatment, 2015, 42(09): 911-914. DOI: 10.3971/j.issn.1000-8578.2015.09.011
    [10]GUO Tianxing, PAN Xiaojie, OU Debin, YE Mingfan. Relationship of Clinical Characteristics and EGFR, K-RAS Mutation in Lung Adenocarcinoma Patients with Predominant Ground-glass Opacity[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1313-1317. DOI: 10.3971/j.issn.1000-8578.2014.12.013

Catalog

    Get Citation
    PDF
    XML
    Article views (2660) PDF downloads (570) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    Related Articles

    Download Center

    Links

    Contact Us

    Address：116 Zhuodaoquan South Road,
    Hongshan District, Wuhan（430079）

    Tel：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    Email Alert RSS
    Total visits：11992116 Visits today：28420

    Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return